Rocket Lab's (RKLB) recent momentum stems from a record launch cadence of 18 Electron missions through September 2026 and a landmark 20-launch contract with Synspective, the largest commercial Electron deal in company history, pushing total backlog above 100 missions. Q2 revenue rose 62% year-over-year to $234 million with backlog reaching $2.36 billion, while the pending $8 billion Iridium acquisition advanced with shareholder approval and cleared initial regulatory hurdles. The stock, recently trading near $65–68 after earlier volatility, reflects trader focus on execution risks for the Neutron rocket's Q4 debut and the November 9 earnings release, against analyst consensus targets averaging around $106–111.